Galecto Reports Completion Of Enrollment In Phase 2b GALACTIC-1 Trial Of GB0139 For Treatment Of Idiopathic Pulmonary Fibrosis
GB0139 is Galecto’s proprietary inhaled once-daily small molecule galectin-3 inhibitor
GALACTIC-1 trial on track to deliver top-line results in mid-2023
BOSTON, April 26, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc.
Galecto Reports Completion Of Enrollment In Phase 1b/2a GULLIVER-2 Trial Of Its GB1211 In LIver Cirrhosis; ‘Top-line results from GULLIVER-2 trial on track for Q4’22’
Top-line results from GULLIVER-2 trial on track for the fourth quarter of 2022
Part 1 of GULLIVER-2 trial completed with positive results as previously announced in December 2021
BOSTON, March 29, 2022 (GLOBE NEWSWIRE)
Executives Buy Over $2.2M Of 3 Penny Stocks
The Nasdaq Composite jumped by 1.2% on Thursday. Investors, meanwhile, focused on some notable insider trades.
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Galecto Says Has Enrolled 10 Of Anticipated 16 Patients In Phase 2a MYLOX-1 Trial; Reiterates Expected Timing Of Multiple Data Readouts In 2022
Company has enrolled 10 of the targeted 16 patients in the trial
Anticipates interim data in mid-2022 and topline data from full trial in 2H 2022
BOSTON, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc.
Galecto To Test GB1211 Combined with Roche’s Tecentriq In First Line Lung Cancer Setting
Galecto Inc (NASDAQ:GLTO) has entered into a clinical trial supply agreement with Roche Holdings AG (OTC:RHHBY) to explore the combination of GB1211 in…
Galecto Announces Clinical Collaboration With Roche For Phase 2 Trial Of GB1211 In Combination With Atezolizumab In First Line Non-Small-Cell Lung Cancer
Galecto, Inc. (NASDAQ:GLTO), a publicly listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that it has entered into a clinical trial supply agreement with
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 7)
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 6)